Corporate News

Tracy George, MD (third from right), ARUP’s chief scientific officer and president of the Innovation Business Unit, holds a zebra, the mascot for patients with rare diseases, and poses for a photo with participants in Salt Lake City’s Rare Disease Day event. Pictured, from left to right, are Tanner Withers, parent of a child with a rare disease, Troy Evans, undiagnosed patient with a rare disease, Rebecca Yates, parent of a child with a rare disease, Matt Pearl, patient with a rare disease, Ava and Lucy Szajunk, undiagnosed patients with rare diseases, George, Chris Gibson, PhD, CEO of Recursion, and Kelvyn Cullimore, president and CEO of BioUtah.

Accurate diagnosis and treatment of cardiovascular conditions are key to patient health. ARUP Consult^® offers current resources for testing to aid clinicians.

MetaCensus is built to support the exchange and review of data by various stakeholders and performs multicriteria decision analysis (MCDA) to assess and account for varying perspectives, counterpoints, and biases.

ARUP medical directors and scientists advanced laboratory medicine and improved patient care with publication of more than 130 peer-reviewed articles in fiscal year 2023.

Julio Delgado, MD, MS, ARUP executive vice president and vice chair and chief of Clinical Pathology at the University of Utah, said he is honored to serve as the inaugural Harry R. Hill, MD, Presidential Endowed Chair and continue his mentor’s work in the field of immunology.

From left to right: Nermin Uvejzovik, Staci Beck, Aubrie Smith, Mitzi Irish, Carrie Pederson, and Derek Gleue accept their third place award in the annual Pipetting Challenge. Not pictured: Sheri Mitchell, Wendy Dong, Cindy Kuo, and Kris Moore.

Madhu Menon, MD, PhD, FCAP, ARUP’s section chief of Hematopathology, works with a team of experts to deliver accurate and timely results.

Utah Business magazine has honored ARUP Laboratories with a 2023 Best Companies to Work For Award. ARUP has earned this award every year since 2018.

Jonathan Genzen, MD, PhD (left), chief medical officer and senior director of governmental affairs, and Jonathan Carr, JD (right), compliance officer, prepare for ARUP’s webinar on the FDA’s proposed rule to regulate lab-developed tests.

ARUP Laboratories has released the company’s public comment in response to the FDA’s plan to regulate LDTs.

Jonathan Genzen, MD, PhD (left), chief medical officer and senior director of governmental affairs, will lead the webinar, and Jonathan Carr, JD (right), compliance officer, will moderate a Q&A session.